Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy

Journal of Cardiovascular Pharmacology

Volumn 63, Issue 2, 2014, Pages 167-177

  Althurwi, Hassan N ^a   Elshenawy, Osama H ^a   El Kadi, Ayman O S ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

20 HETE; Cardiovascular disease; Cytochrome P450; EETs; Fenofibrate

Indexed keywords

8,11,14-EICOSATRIENOIC ACID; ANIMALS; ARACHIDONIC ACID; CARDIOMEGALY; CYTOCHROME P-450 ENZYME SYSTEM; FENOFIBRATE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; HYDROXYEICOSATETRAENOIC ACIDS; HYPOLIPIDEMIC AGENTS; ISOPROTERENOL; MALE; RATS; RATS, SPRAGUE-DAWLEY;

EID: 84894035729     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0000000000000036     Document Type: Article

References (57)

1. Canada HaSFo. The Growing Burden of Heart Disease and Stroke in Canada. Heart and Stroke Foundation of Canada: Ottawa, Canada; 2003
2. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: A report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2009;119:e21-e181
3. Canada CBo. The Canadian Heart Health Strategy: Risk Factors and Future Cost Implications. In: Louis Thèriault CS, Browarski S, eds. The Conference Board of Canada: Ottowa, Canada; 2010
4. Sacks FM. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: A role for fenofibrate. Introduction. Am J Cardiol. 2008;102:1L-3L
5. Elbekai RH, El-Kadi AO. Cytochrome P450 enzymes: Central players in cardiovascular health and disease. Pharmacol Ther. 2006;112:564-587
6. Roman RJ. P-450 metabolites of arachidonic acid in the control of cardiovascular function. Physiol Rev. 2002;82:131-185
7. Imig JD, Zhao X, Capdevila JH, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension. Hypertension. 2002;39:690-694
8. Spector AA, Fang X, Snyder GD, et al. Epoxyeicosatrienoic acids (EETs): Metabolism and biochemical function. Prog Lipid Res. 2004; 43:55-90
9. Campbell WB, Gebremedhin D, Pratt PF, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors. Circ Res. 1996;78:415-423
10. Node K, Huo Y, Ruan X, et al. Anti-inflammatory properties of cytochrome P450 epoxygenase-derived eicosanoids. Science. 1999;285: 1276-1279
11. Michaelis UR, Fisslthaler B, Barbosa-Sicard E, et al. Cytochrome P450 epoxygenases 2C8 and 2C9 are implicated in hypoxia-induced endothelial cell migration and angiogenesis. J Cell Sci. 2005;118:5489-5498
12. Miyata N, Roman RJ. Role of 20-hydroxyeicosatetraenoic acid (20-HETE) in vascular system. J Smooth Muscle Res. 2005;41:175-193
13. Ishizuka T, Cheng J, Singh H, et al. 20-Hydroxyeicosatetraenoic acid stimulates nuclear factor-kappaB activation and the production of inflammatory cytokines in human endothelial cells. J Pharmacol Exp Ther. 2008;324:103-110
14. Balakumar P, Rohilla A, Mahadevan N. Pleiotropic actions of fenofibrate on the heart. Pharmacol Res. 2011;63:8-12
15. Keech A, Simes RJ, Barter P, et al. Effects of long-Term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): Randomised controlled trial. Lancet. 2005; 366:1849-1861
16. Delerive P, Fruchart JC, Staels B. Peroxisome proliferator-Activated receptors in inflammation control. J Endocrinol. 2001;169:453-459
17. Zou J, Le K, Xu S, et al. Fenofibrate ameliorates cardiac hypertrophy by activation of peroxisome proliferator-Activated receptor-Alpha partly via preventing p65-NFkappaB binding to NFATc4. Mol Cell Endocrinol. 2013;370:103-112
18. Chen HJ, Chen JZ, Wang XX, et al. PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats [in Chinese]. Zhejiang Da Xue Xue Bao Yi Xue Ban. 2007;36:470-476
19. Ogata T, Miyauchi T, Sakai S, et al. Stimulation of peroxisomeproliferator-Activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts. Clin Sci (Lond). 2002;103(suppl 48):284S-288S
20. Diep QN, Benkirane K, Amiri F, et al. PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats. J Mol Cell Cardiol. 2004;36:295-304
21. Zhao X, Li LY. PPAR-Alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats. Am J Nephrol. 2008;28:598-606
22. Zhao X, Quigley JE, Yuan J, et al. PPAR-Alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats. Am J Physiol Heart Circ Physiol. 2006;290:H2187-H2195
23. Huang H, Morisseau C, Wang J, et al. Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats. Am J Physiol Renal Physiol. 2007;293:F342-F349
24. Muller DN, Theuer J, Shagdarsuren E, et al. A peroxisome proliferatoractivated receptor-Alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury. Am J Pathol. 2004;164: 521-532
25. Zordoky BN, Anwar-Mohamed A, Aboutabl ME, et al. Acute doxorubicin toxicity differentially alters cytochrome P450 expression and arachidonic acid metabolism in rat kidney and liver. Drug Metab Dispos. 2011;39: 1440-1450
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-Time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 2001;25:402-408
27. Barakat MM, El-Kadi AO, du Souich P. L-NAME prevents in vivo the inactivation but not the down-regulation of hepatic cytochrome P450 caused by an acute inflammatory reaction. Life Sci. 2001;69:1559-1571
28. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951;193:265-275
29. Gharavi N, El-Kadi AO. tert-Butylhydroquinone is a novel aryl hydrocarbon receptor ligand. Drug Metab Dispos. 2005;33:365-372
30. Nithipatikom K, Grall AJ, Holmes BB, et al. Liquid chromatographicelectrospray ionization-mass spectrometric analysis of cytochrome P450 metabolites of arachidonic acid. Anal Biochem. 2001;298:327-336
31. Morisseau C, Hammock BD. Measurement of soluble epoxide hydrolase (sEH) activity. Curr Protoc Toxicol. 2007;Chapter 4:Unit 4 23, pp 1-18
32. Zordoky BN, El-Kadi AO. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and beta-naphthoflavone induce cellular hypertrophy in H9c2 cells by an aryl hydrocarbon receptor-dependant mechanism. Toxicol In Vitro. 2010;24: 863-871
33. Thum T, Borlak J. Testosterone, cytochrome P450, and cardiac hypertrophy. FASEB J. 2002;16:1537-1549
34. Zordoky BN, El-Kadi AO. Modulation of cardiac and hepatic cytochrome P450 enzymes during heart failure. Curr Drug Metab. 2008;9:122-128
35. Michaelis UR, Fisslthaler B, Medhora M, et al. Cytochrome P450 2C9-derived epoxyeicosatrienoic acids induce angiogenesis via cross-Talk with the epidermal growth factor receptor (EGFR). FASEB J. 2003;17: 770-772
36. Fleming I. Epoxyeicosatrienoic acids, cell signaling and angiogenesis. Prostaglandins Other Lipid Mediat. 2007;82:60-67
37. Imig JD. Epoxides and soluble epoxide hydrolase in cardiovascular physiology. Physiol Rev. 2012;92:101-130
38. Zhang Y, El-Sikhry H, Chaudhary KR, et al. Overexpression of CYP2J2 provides protection against doxorubicin-induced cardiotoxicity. Am J Physiol Heart Circ Physiol. 2009;297:H37-H46
39. Seubert J, Yang B, Bradbury JA, et al. Enhanced postischemic functional recovery in CYP2J2 transgenic hearts involves mitochondrial ATPsensitive K+ channels and p42/p44 MAPK pathway. Circ Res. 2004; 95:506-514
40. Yang B, Graham L, Dikalov S, et al. Overexpression of cytochrome P450 CYP2J2 protects against hypoxia-reoxygenation injury in cultured bovine aortic endothelial cells. Mol Pharmacol. 2001;60:310-320
41. Monti J, Fischer J, Paskas S, et al. Soluble epoxide hydrolase is a susceptibility factor for heart failure in a rat model of human disease. Nat Genet. 2008;40:529-537
42. Althurwi HN, Tse MM, Abdelhamid G, et al. Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy. Br J Pharmacol. 2013;168:1794-1807
43. El-Sherbeni AA, Aboutabl ME, Zordoky BN, et al. Determination of the dominant arachidonic acid cytochrome P450 monooxygenases in rat heart, lung, kidney, and liver: Protein expression and metabolite kinetics. AAPS J. 2012
44. Schladt L, Hartmann R, Timms C, et al. Concomitant induction of cytosolic but not microsomal epoxide hydrolase with peroxisomal beta-oxidation by various hypolipidemic compounds. Biochem Pharmacol. 1987;36:345-351
45. Elshenawy OH, Anwar-Mohamed A, Abdelhamid G, El-Kadi AO. Murine atrial HL-1 cell line is a reliable model to study drug metabolizing enzymes in the heart. Vascul Pharmacol. 2013;58:326-333
46. Wang MH, Guan H, Nguyen X, et al. Contribution of cytochrome P-450 4A1 and 4A2 to vascular 20-hydroxyeicosatetraenoic acid synthesis in rat kidneys. Am J Physiol. 1999;276:F246-F253
47. Aboutabl ME, Zordoky BN, Hammock BD, et al. Inhibition of soluble epoxide hydrolase confers cardioprotection and prevents cardiac cytochrome P450 induction by benzo(a)pyrene. J Cardiovasc Pharmacol. 2011;57:273-281
48. Elshenawy OH, Anwar-Mohamed A, El-Kadi AO. 20-Hydroxyeicosatetraenoic acid is a potential therapeutic target in cardiovascular diseases. Curr Drug Metab. 2013;14:706-719
49. Gross ER, Nithipatikom K, Hsu AK, et al. Cytochrome P450 omegahydroxylase inhibition reduces infarct size during reperfusion via the sarcolemmal KATP channel. J Mol Cell Cardiol. 2004;37: 1245-1249
50. Aboutabl ME, Zordoky BN, El-Kadi AO. 3-methylcholanthrene and benzo(a)pyrene modulate cardiac cytochrome P450 gene expression and arachidonic acid metabolism in male Sprague Dawley rats. Br J Pharmacol. 2009;158:1808-1819
51. Tse MM, Aboutabl ME, Althurwi HN, et al. Cytochrome P450 epoxygenase metabolite, 14,15-EET, protects against isoproterenol-induced cellular hypertrophy in H9c2 rat cell line. Vascul Pharmacol. 2013;58: 363-373
52. Cui X, Kawashima H, Barclay TB, et al. Molecular cloning and regulation of expression of two novel mouse CYP4F genes: Expression in peroxisome proliferator-Activated receptor alpha-deficient mice upon lipopolysaccharide and clofibrate challenges. J Pharmacol Exp Ther. 2001;296:542-550
53. Kawashima H, Kusunose E, Thompson CM, et al. Protein expression, characterization, and regulation of CYP4F4 and CYP4F5 cloned from rat brain. Arch Biochem Biophys. 1997;347:148-154
54. Palut D, Kostka G, Strucinski P. The role of nuclear receptors in cytochrome P-450 induction by xenochemicals [in Polish]. Rocz Panstw Zakl Hig. 2002;53:321-332
55. Bernardo BC, Weeks KL, Pretorius L, et al. Molecular distinction between physiological and pathological cardiac hypertrophy: Experimental findings and therapeutic strategies. Pharmacol Ther. 2010;128:191-227
56. Irukayama-Tomobe Y, Miyauchi T, Sakai S, et al. Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferatoractivated receptor-Alpha partly via blockade of c-Jun NH2-Terminal kinase pathway. Circulation. 2004;109:904-910
57. Lebrasseur NK, Duhaney TA, De Silva DS, et al. Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension. Hypertension. 2007;50:489-496